Drugs / AMG 529
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03170193 | May → Nov 2017 | cardiovascular disorder | Amgen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 529 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03170193 ↗ |
| Route | Intravenous | “by subcutaneous (SC) or intravenous (IV) injection” NCT03170193 ↗ |
| Route | Subcutaneous | “by subcutaneous (SC) or intravenous (IV) injection” NCT03170193 ↗ |